(Q57396224)

English

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (

article

In more languages

Statements

scholarly article

0 references

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE ( (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systolic heart failure

1 reference

based on heuristic

inferred from title

object named as

John J.V. McMurray

6

0 references

5

object named as

Lars Kober

0 references

1

object named as

Henry Krum

0 references

Kenneth Dickstein

4

object named as

Kenneth Dickstein

0 references

William T Abraham

3

object named as

William T. Abraham

0 references

Claudio R Gimpelewicz

8

object named as

Claudio Gimpelewicz

0 references

Barry M. Massie

2

object named as

Barry Massie

0 references

Bernard Reimund

10

object named as

Bernard Reimund

0 references

author name string

Ashkay Desai

7

0 references

Albert Kandra

9

0 references

Henning Rattunde

11

0 references

Juergen Armbrecht

12

0 references

publication date

January 2011

0 references

European Journal of Heart Failure

0 references

13

0 references

1

0 references

107-114

0 references

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Current concepts in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

A graphical approach to sequentially rejective multiple test procedures

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

BNP and congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ212

21 January 2018

Identifiers

10.1093/EURJHF/HFQ212

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57396224&oldid=1744703530"